Rigel Pharmaceuticals, Inc.: dividend

RIGLNASDAQHealthcare · Pharmaceutical Preparations

Price

$44.46

November 13, 2026Market cap $821M

What Ploutos Investor adds for Rigel Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

Rigel Pharmaceuticals pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 3.4% in a year.

All dividend stocks

The full analysis

What do Rigel Pharmaceuticals's filings show?

The dividend is one part of Rigel Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RIGL's dividend

Didn't find what you were looking for?

Ask us
Does RIGL pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 3.4% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.